Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.
作者： Jacqueline M Dempsey , Kelley M Kidwell , Christina L Gersch , Andrea M Pesch , Zeruesenay Desta
关键词: Estrone sulfate 、 Exemestane 、 Aromatase 、 Internal medicine 、 Aromatase inhibitor 、 Medicine 、 Breast cancer 、 Estrone 、 Estrogen 、 Letrozole 、 Endocrinology
摘要: Aim: This study tested for associations between SLCO1B1 polymorphisms and circulating estrogen levels in women with breast cancer treated letrozole or exemestane. Patients & methods: Postmenopausal hormone-receptor positive were genotyped SLCO1B1*5 (rs4149056) rs10841753. Pretreatment on-treatment plasma estrogens aromatase inhibitor (AI) concentrations measured. Regression analyses performed to test pharmacogenetic drug concentrations. Results: was associated elevated pretreatment estrone sulfate an increased risk of detectable after 3 months AI treatment. Conclusion: These findings suggest may have effect on estrogenic response treatment, therefore adversely impact the anticancer effectiveness these agents.
elsevier.com
sci-hub.se 参考文章(32)
Endogenous Hormones and Breast Cancer Collaborative Group, None, Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute. ,vol. 94, pp. 606- 616 ,(2002) , 10.1093/JNCI/94.8.606
A Kalliokoski, M Niemi, Impact of OATP transporters on pharmacokinetics British Journal of Pharmacology. ,vol. 158, pp. 693- 705 ,(2009) , 10.1111/J.1476-5381.2009.00430.X
James N. Ingle, Aman U. Buzdar, Daniel J. Schaid, Matthew P. Goetz, Anthony Batzler, Mark E. Robson, Donald W. Northfelt, Janet E. Olson, Edith A. Perez, Zeruesenay Desta, Randy A. Weintraub, Clark V. Williard, David A. Flockhart, Richard M. Weinshilboum, Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer Cancer Research. ,vol. 70, pp. 3278- 3286 ,(2010) , 10.1158/0008-5472.CAN-09-3024
Z Desta, Y Kreutz, A T Nguyen, L Li, T Skaar, L K Kamdem, N L Henry, D F Hayes, A M Storniolo, V Stearns, E Hoffmann, R F Tyndale, D A Flockhart, Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age Clinical Pharmacology & Therapeutics. ,vol. 90, pp. 693- 700 ,(2011) , 10.1038/CLPT.2011.174
N. Lynn Henry, Jon T. Giles, Dennis Ang, Monika Mohan, Dina Dadabhoy, Jason Robarge, Jill Hayden, Suzanne Lemler, Karineh Shahverdi, Penny Powers, Lang Li, David Flockhart, Vered Stearns, Daniel F. Hayes, Anna Maria Storniolo, Daniel J. Clauw, Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Research and Treatment. ,vol. 111, pp. 365- 372 ,(2008) , 10.1007/S10549-007-9774-6
Dia Smiley, Raouf Khalil, Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Current Medicinal Chemistry. ,vol. 16, pp. 1863- 1887 ,(2009) , 10.2174/092986709788186093
CHIARA GHIMENTI, MAURIZIA MELLO-GRAND, ENRICO GROSSO, MARIA SCATOLINI, LEA REGOLO, ALBERTO ZAMBELLI, GIOVANNA CHIORINO, Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy Experimental and Therapeutic Medicine. ,vol. 5, pp. 902- 906 ,(2013) , 10.3892/ETM.2012.878
Susan B. Brown, Susan E Hankinson, Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids. ,vol. 99, pp. 8- 10 ,(2015) , 10.1016/J.STEROIDS.2014.12.013
Yoshihisa Shitara, Clinical Importance of OATP1B1 and OATP1B3 in DrugDrug Interactions Drug Metabolism and Pharmacokinetics. ,vol. 26, pp. 220- 227 ,(2011) , 10.2133/DMPK.DMPK-10-RV-094
Liewei Wang, Katarzyna A. Ellsworth, Irene Moon, Linda L. Pelleymounter, Bruce W. Eckloff, Yvette N. Martin, Brooke L. Fridley, Gregory D. Jenkins, Anthony Batzler, Vera J. Suman, Saranya Ravi, J. Michael Dixon, William R. Miller, Eric D. Wieben, Aman Buzdar, Richard M. Weinshilboum, James N. Ingle, Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Research. ,vol. 70, pp. 319- 328 ,(2010) , 10.1158/0008-5472.CAN-09-3224